comparemela.com

Latest Breaking News On - Nasdaq mrvi - Page 1 : comparemela.com

Maravai LifeSciences (MRVI) Scheduled to Post Quarterly Earnings on Wednesday

Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) will be announcing its earnings results after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.03) per share for the quarter. Maravai LifeSciences has set its FY 2024 guidance at EPS.Investors that are interested in participating in the company’s conference call […]

Maravai LifeSciences (NASDAQ:MRVI) Trading Down 2 9%

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Free Report) traded down 2.9% on Wednesday . The company traded as low as $7.81 and last traded at $7.90. 268,444 shares traded hands during mid-day trading, a decline of 90% from the average session volume of 2,618,730 shares. The stock had previously closed at $8.14. Analyst Upgrades […]

Maravai LifeSciences Holdings, Inc (NASDAQ:MRVI) Receives $13 22 Consensus Target Price from Analysts

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average […]

Maravai LifeSciences (NASDAQ:MRVI) Shares Gap Up to $5 11

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Free Report)’s stock price gapped up prior to trading on Friday . The stock had previously closed at $5.11, but opened at $6.95. Maravai LifeSciences shares last traded at $7.96, with a volume of 5,625,671 shares trading hands. Wall Street Analyst Weigh In A number of research firms […]

Maravai LifeSciences Holdings, Inc (NASDAQ:MRVI) Receives Average Recommendation of Moderate Buy from Brokerages

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the eight analysts that are presently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month target […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.